Fermenta Biotech Secures Prestigious CEP for Vitamin D3 Variant
Fermenta Biotech Limited has received the Certificate of Suitability from the European Directorate for its VITADEE™ 100 SD. This positions Fermenta as one of the two companies globally accredited for this Vitamin D3 variant. The accomplishment highlights its commitment to high-quality standards and strengthens its global market presence.

- Country:
- India
Fermenta Biotech Limited, a leader in pharmaceutical and nutritional ingredients, has achieved a significant milestone by receiving the Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & Healthcare (EDQM) for its innovative Spray–Dried variant VITADEE™ 100 SD - Cholecalciferol Concentrate.
Manufactured at Fermenta's Kullu facility in Himachal Pradesh, the product positions the company as one of the only two globally to hold such an accreditation for this variant of Vitamin D3. This approval underscores Fermenta's adherence to stringent European Pharmacopoeial Standards.
Managing Director Mr. Prashant Nagre highlighted that this achievement elevates Fermenta's global standing in the Vitamin D3 industry, paving the way for further expansion and reinforcing its dedication to excellence and innovation in health and nutrition.
(With inputs from agencies.)
ALSO READ
India's Health Revolution: PM Modi and Dr. Charu Sadana Advocate for Transparency in Food Labels
Global Health Sector Shake-ups and Innovations
NZ Expands Pathway for Foreign Doctors, Boosts Health Workforce Capacity
From Plans to Pitfalls: Why DRC’s Health Budget Isn’t Reaching Its People
New FDA Health Claim Highlights Yogurt’s Potential to Reduce Type 2 Diabetes Risk